InnoCan Pharma Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INNO.CN research report →
Price Chart
About the company
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes.
- CEO
- Iris Bincovich
- IPO
- 2019
- Employees
- 11
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on INNO.CN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.45M
- P/E
- -4.62
- PEG
- 0.05
- P/S
- 0.27
- P/B
- 1.32
- EV/EBITDA
- -2.34
- Div Yield
- 0.00%
- Gross Margin
- 89.81%
- Op Margin
- -10.00%
- Net Margin
- -5.95%
- ROE
- -31.76%
- ROIC
- -26.92%
Latest fiscal year · YoY change
- Revenue
- $26.61M-9.6%
- Gross Profit
- $23.93M-8.6%
- Op Income
- $-1,255,000
- Net Income
- $-1,124,000+38.7%
- EPS
- $-0.25+40.5%
- OCF Growth
- +131.3%
- FCF Growth
- +130.1%
- 52W High
- $21.00
- 52W Low
- $2.00
- 50D MA
- $2.94
- 200D MA
- $6.44
- Beta
- -0.22
- RSI (14)
- 37
- Avg Volume
- 1.20K
No earnings-call transcripts are available for INNO.CN yet.
- Free Float
- 79.6%
- Shares Outstanding
- 4.50M
- Float Shares
- 3.58M
Our INNO.CN coverage
Recent articles, reports, and earnings notes.
No research on INNO.CN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INNO.CN report →Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust
prnewswire.com · Aug 5
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
prnewswire.com · May 27
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
prnewswire.com · Mar 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.